Vyome Holdings (HIND) risk factors
Item 1A of every Vyome Holdings, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors72 risks53 new68 dropped16 reworded
Clinical-stage biopharmaceutical company focused on developing VT-1953 and VT-1908 following a corporate merger. Faces substantial operating losses, lack of commercial revenue, and significant capital raising requirements. Insider ownership is highly concentrated at over seventy-four percent.
Filed Mar 18, 2026 - FY2024 10-K risk factors87 risks
The company faces severe going concern risks, heavily dependent on closing its pending merger with Vyome. Operations and liquidity are severely strained by cash burn and GLP-1 weight loss drugs. Substantial dilution hangs over stockholders from pending warrant exercises and future capital raises.
Filed Apr 04, 2025